Gastrointestinal safety profile of nabumetone: a meta-analysis

摘要: Individual comparative studies suggest that nabumetone has a gastrointestinal (GI) safety profile superior to comparator NSAIDs but lack power show statistical difference. The aim of this study was evaluate systematically the difference in GI adverse events--especially rate perforations, ulcers, and bleeds (PUBs)-- between studies, meta-analyses trials conventional NSAIDs, postmarketing, open-label meeting predefined inclusion exclusion criteria. A fully recursive literature search identified 13 consisting 29 treatment arms 49,501 patients met Tests for heterogeneity found no significant each subgroup. Overall, dyspeptic symptoms flatulence, constipation, diarrhea were most commonly reported events accounting 98.6% total events. Significantly more treated with NSAID experienced than did those taking (P = 0.007). After adjustment patient-exposure years, PUBs 10 36 times likely develop nabumetone. This consistently seen nonendoscopic (n 7,468) endoscopic 244). In analysis postmarketing or nabumetone, only one PUB per 500 years over 17,502 39,389). event-related dropouts hospitalizations increased by 1.3- 3.7-fold if fewer treatment-related events, especially PUBs, are NSAID. Nabumetone is very safe tract.